Renal and Metabolic Effects of Insulin Lispro in Type 2 Diabetic Subjects With Overt Nephropathy
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE—To assess whether the insulin analog lispro may antagonize the renal effects of IGF-1, a mediator of glomerular hyperfiltration involved in the progression of diabetic and nondiabetic chronic nephropathies. RESEARCH DESIGN AND METHODS—In a randomized crossover study, we compared the renal and metabolic responses to regular or lispro insulin (0.1 units/kg body wt) administered after a euglycemic clamp and 5 and 30 min before a standard meal to 11 type 2 diabetic patients with macroalbuminuria. RESULTS—Two- and four-hour postprandial changes (vs. preprandial euglycemia) in glomerular filtration rate (GFR) followed a significantly different trend (5.8 ± 5.0 vs. −6.3 ± 4.7, P < 0.05; and 11.0 ± 6.8 vs. 0.7 ± 5.1%, P < 0.05) after regular insulin and lispro injection, respectively. After lispro, postprandial GFR changes were negatively correlated (r = −0.48, P = 0.0001) with plasma insulin concentration. After regular insulin, renal plasma flow increased in parallel with a decrease in renal vascular resistances. Both changes were fully prevented by lispro. Postprandial blood glucose maximum concentration (278 ± 16 vs. 240 ± 16 mg/dl, P < 0.01) and area under the curve (79,381 ± 19,237 vs. 72,810 ± 16,211 mg/dl per min, P < 0,05) were significantly lower after insulin lispro than after regular insulin injection, respectively, despite comparable postprandial insulin profiles. Changes in total and gluconeogenic amino acids followed a similar trend. Changes in blood glucose and plasma amino acids did not correlate with concomitant changes in GFR. CONCLUSIONS—In overt nephropathy of type 2 diabetes, lispro prevents glomerular hyperfiltration and offsets the renal effects of meal or meal-associated hyperglycemia by mechanisms possibly related to IGF-1 antagonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Polyphenols with antiglycation activity and mechanisms of action: A review of recent findings
Yeh, W.-J., Hsia, S.-M., Lee, W.-H., & Wu, C.-H. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2016.10.017 · Cited by 353
Insulin therapy in renal disease
Iglesias, P., & Díez, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00802.x · Cited by 110
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.016 · Cited by 9
“A randomized crossover study evaluated use of the short-acting insulin analogue lispro in patients with decreased kidney function and demonstrated improvement in glycemic control and safety compared with regular insulin.(38) We also noted that insulin use in lowincome subsidy patients was higher than in non–low-income…”
Method
Metadata
- Authors
- Ruggenenti, P., Flores, C., Aros, C., Ene-Iordache, B., Trevisan, R., Ottomano, C., & Remuzzi, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-02-01
- Volume
- 26
- Issue
- 2
- Pages
- 502-509
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2039728209
- Cited by
- 24
- References
- 0
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal and Metabolic Effects of Insulin Lispro in Type 2 Diabetic Subjects With Overt Nephropathy. https://app.cochat.ai/papers/10.2337/diacare.26.2.502
- The paper
- Ruggenenti, P., Flores, C., Aros, C., Ene-Iordache, B., Trevisan, R., Ottomano, C., & Remuzzi, G. (2003). Renal and Metabolic Effects of Insulin Lispro in Type 2 Diabetic Subjects With Overt Nephropathy. Diabetes Care. https://doi.org/10.2337/diacare.26.2.502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.